Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Ticker
Market factors today
Unlock the full CVKD picture
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD stock facts
| Ticker symbol | CVKD |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $4.1M |
| CEO | Quang X. Pham |
| Employees | 5 |
| Headquarters | Ponte Vedra, FL, US |
| IPO date | 2023-01-20 |
| Website | www.cadrenal.com |
What you can see for CVKD on Tickr
Live CVKD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CVKD report.
Rankings
FAQ
What is the ticker symbol for Cadrenal Therapeutics, Inc. Common Stock?
The ticker symbol for Cadrenal Therapeutics, Inc. Common Stock is CVKD, listed on the NASDAQ Global Market.
What is CVKD?
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and…